Abstract: A system and methods for determining a mechanical tissue characteristic (?) are provided. The system comprises a providing unit for providing a set of images of a tissue region of interest, wherein the provided set of images comprises image features indicative of one or more structural properties (?, a0, CO, PG) of the tissue region of interest and has been acquired using an imaging modality suitable for in-vivo imaging of the tissue region of interest. The system further comprises a determining unit for determining, based on the provided set of images, a mechanical tissue characteristic (?) indicative of a mechanical responsiveness of the tissue region of interest. The determining unit comprises a machine learning architecture adapted to receive the provided set of images as an input and to provide the mechanical tissue characteristic as an output.

Abstract: In a first aspect, provided herein are chimeric antigen receptors (CAR) composed of at least an extracellular domain, a transmembrane domain and an intracellular domain, the extracellular domain comprises a spacer domain located C-terminally to a ligand-binding-domain also present in the extracellular domain, whereby the spacer domain comprises at least part of the CD34 molecule. Also provided are nucleic acid molecules encoding the same as well as vectors and cells containing the same. The cells include engineered T-cells and NK-cells and derivatives thereof. A pharmaceutical composition comprising the CAR e.g. in form of a vector, a polynucleotide encoding the CAR or the CAR itself and, in addition, cells, cell lines or host cells accordingly are provided. The CAR is useful in adoptive cell therapy. Finally, a method for enrichment or purification of CAR, in particular, of genetically engineered cells, cell lines or host cells expressing the CAR is provided.

Abstract: The present invention relates to transgenic plants with altered photorespiration and improved CO2 fixation as well as a method of producing said transgenic plants. Particularly, the transgenic plants show an improved growth rate, productivity and energy conversion efficiency. This method can be successfully applied to many agricultural crop plants with nutritional and medicinal uses.

Abstract: The present invention relates to a compound reducing microtubule detyrosination in axonal tips selected from the group consisting of tubulin carboxypeptidase inhibitors and tubulin tyrosine ligase activators and combinations thereof for use in the treatment of axonal damage.

Abstract: The present invention relates to a compound reducing microtubule detyrosination in axonal tips selected from the group consisting of tubulin carboxypeptidase inhibitors and tubulin tyrosine ligase activators and combinations thereof for use in the treatment of axonal damage.

Abstract: The present invention refers to a sensor (10) having a layer arrangement (12), wherein the layer arrangement (12) comprises at least a base layer (14), a middle layer (16) and an outer layer (18), wherein the middle layer (16) is arranged at least partly upon and in contact with the base layer (14) and wherein the outer layer (18) is arranged at least partly upon and in contact with the middle layer (16), wherein the base layer (14) comprises a metal, wherein the middle layer (16) comprises a metal oxide, and wherein the outer layer (18) is porous and comprises a material selected from the group comprising electrically conductive carbon compounds such as, more particularly, graphite or carbon nanotubes (CNTs), organic electrical conductors and base metals, and wherein electrical contacts can be formed with the base layer (14) and outer layer (18) for a conductivity measurement and/or a resistance measurement.

Abstract: The present invention provides oligonucleotides and processes for determining the normalized methylation level of DNA, and for determining the relative methylation level of DNA between at least two samples. The invention makes use of the random distribution of transposons in the genome. The disclosed oligonucleotides and processes are of importance, in particular, for clinical diagnostics.

Abstract: The present invention relates to a nucleic acid molecule for recombinant expression and secretion of a peptide or protein of interest comprising a hemolysin A and/or hemolysin C-derived nucleotide sequence, fragments thereof, homologs thereof, or the complements thereof, and a nucleotide sequence encoding the peptide or protein of interest.

Abstract: The present invention relates to the use of a compound, a salt or solvate thereof as C4 plant selective herbicide wherein said compound has a structure according to formula (I) wherein A is a cyclic alkyl, aryl, heterocycloalkyl, or heteroaryl group, and B is a cyclic alkyl, aryl, heterocycloalkyl, or heteroaryl group, and wherein R1, R2, R3, R4 and R5 are, independently of each other H or an alkyl group, and wherein integer i is 0 or 1, preferably 1, and the bond (a) is a single or double bond, and wherein in case (a) is a double bond, n is 0 and X is O or S, and wherein in case (a) is a single bond n is 1, and X is H or an alkyl group, and wherein the bond (b) is a single or double bond, and wherein in case (b) is a double bond, m and p are 0, and wherein in case (b) is a single bond m and p are both 1, and/or according to formula (II) including tautomeric structures thereof, wherein R01 and R02 are independently of each other selected from the group consisting of H, OH, carboxylic acid, ester, alkyl, alkox

Abstract: The invention relates to a HNK-I mimetic peptide or a polypeptide comprising such HNK-I mimetic peptide for treating or preventing a Pseudomonas infection, in particular an infection with Pseudomonas aeruginosa. The invention further relates to the use of a HNK-I mimetic peptide or a polypeptide comprising such HNK-I mimetic peptide for the preparation of a pharmaceutical composition for treating or preventing a Pseudomonas infection. The invention also relates to a pharmaceutical composition comprising a HNK-I mimetic peptide or a polypeptide comprising such HNK-I mimetic peptide, wherein the composition is for treating or preventing a Pseudomonas infection.

Abstract: A composition includes D-peptides or antibodies to at least one of to prevent a disease and to treat the disease, wherein the D-peptides interact with an amyloid peptide and the antibodies bind to both the D-peptide and the amyloid peptide.

Abstract: The invention relates to a method for monitoring and/or regulating fuel cells, in particular comprising determining the composition of the operating gases of the fuel cells. The method comprises the following steps: introducing the gas mixture to be analyzed into a measuring cell (1); producing an arc in the measuring cell (1); absorbing the radiation emitted by the arc; optical filtering of the emitted radiation and/or spectral decomposition of the emitted radiation; converting the emitted radiation into an electric signal; evaluating the electric signal.

Abstract: The invention discloses in vitro methods and a system for determining a predisposition of a subject for developing a cancer on the basis of analyzing a sample of the subject for an alteration of at least one allele of the RAD51C gene. Further disclosed are in vitro methods for assessing clinical features or a pathological progression of a cancer and for assessing at least one RAD51 C gene alteration in a cell. In addition a kit for determining a predisposition of a subject for developing a cancer, and certain uses of oligonucleotides for determining the presence of at least one mono-allelic germ-line mutation of the RAD51C gene.

Abstract: The present invention relates to a nucleic acid molecule for recombinant expression and secretion of a peptide or protein of interest comprising a hemolysin A and/or hemolysin C-derived nucleotide sequence, fragments thereof, homologs thereof, or the complements thereof, and a nucleotide sequence encoding the peptide or protein of interest.

Abstract: A phosphorylated A2A receptor agonist providing agonist properties on the A2A receptor after dephosphorylation the phosphorylated A2A receptor agonist comprises a ribosyl moiety and a purine moiety and being phosphorylated at the 5?-position of the ribose moiety except adenosine monophosphate (AMP), adenosine diphosphate (ADP) or adenosine triphosphate (ATP), a medicament containing the compound of the invention including ADP and the use of the compound of the invention including ATP and ADP for several medical indications e.g. inflammatory events. In particular, compounds of formula (I) are also disclosed.

Abstract: The invention relates to a method for monitoring and/or regulating fuel cells, in particular comprising determining the composition of the operating gases of the fuel cells. The method comprises the following steps: introducing the gas mixture to be analyzed into a measuring cell (1); producing an arc in the measuring cell (1); absorbing the radiation emitted by the arc; optical filtering of the emitted radiation and/or spectral decomposition of the emitted radiation; converting the emitted radiation into an electric signal; evaluating the electric signal.

Abstract: It relates to the treatment or prevention of a chronic viral infection with a Thymic Stromal Lymphopoietin (TSLP) antagonist thereby avoiding immune evasion and persistence of the virus. It also provides a method of prognosing the evolution of a cervical dysplasia by TSLP expression in a sample of said cervical dysplasia.

Abstract: The present invention provides oligonucleotides and processes for determining the normalized methylation level of DNA, and for determining the relative methylation level of DNA between at least two samples. The invention makes use of the random distribution of transposons in the genome. The disclosed oligonucleotides and processes are of importance, in particular, for clinical diagnostics.

Abstract: The present invention relates to a composition comprising D-peptides or antibodies for use as a therapeutic and/or for disease prevention, wherein a) the D-peptides interact with an amyloid peptide and b) the antibodies bind to the D-peptide from a) and additionally to the amyloid peptide from a).

Abstract: The invention relates to polymerase inhibitors, particularly polymerase alpha inhibitors, and the use thereof in the treatment of cell growth disorders, particularly tumor disorders, preferably actinic keratoses, basal cell carcinomas, and/or spinocellular carcinomas.